Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.

Raaijmakers R, Houkes LM, Schröder CH, Willems JL, Monnens LA.

Perit Dial Int. 2013 Sep-Oct;33(5):565-72. doi: 10.3747/pdi.2012.00063. Epub 2013 May 1.

2.

The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.

Wilson RJ, Keith MS, Preston P, Copley JB.

Adv Ther. 2013 Dec;30(12):1100-10. doi: 10.1007/s12325-013-0077-5. Epub 2013 Dec 5.

PMID:
24307220
3.

Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.

De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.

Kidney Int. 2013 Jun;83(6):1109-17. doi: 10.1038/ki.2013.34. Epub 2013 Mar 13.

4.

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.

Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M.

Nephrology (Carlton). 2011 Nov;16(8):743-50. doi: 10.1111/j.1440-1797.2011.01509.x.

PMID:
21854503
5.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

6.

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.

Drugs. 2008;68(1):85-104. Review.

PMID:
18081374
7.

Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.

Nolan CR, Qunibi WY.

Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Review.

PMID:
12815333
8.

Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.

Abdullah S, Diezi M, Sung L, Dupuis LL, Geary D, Abla O.

Pediatr Blood Cancer. 2008 Jul;51(1):59-61. doi: 10.1002/pbc.21478.

PMID:
18240167
9.
10.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
11.

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.

Perit Dial Int. 2007 Nov-Dec;27(6):697-701.

PMID:
17984434
12.

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.

Am J Kidney Dis. 2010 Feb;55(2):307-15. doi: 10.1053/j.ajkd.2009.10.051. Epub 2009 Dec 30.

PMID:
20042256
13.
14.

[The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].

Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.

Wiad Lek. 2011;64(1):9-14. Polish.

PMID:
21812357
15.

Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.

Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T.

Ther Apher Dial. 2005 Aug;9(4):347-51.

PMID:
16076380
16.

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N.

Nephrol Dial Transplant. 2009 Dec;24(12):3794-9. doi: 10.1093/ndt/gfp372. Epub 2009 Aug 7.

17.

Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.

Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S; Bixalomer Study Group..

Ther Apher Dial. 2014 Apr;18(2):122-31. doi: 10.1111/1744-9987.12068. Epub 2013 Aug 27.

PMID:
24720402
18.
19.

Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.

Gen S, Sasaki T, Saito K, Nobe K, Nodaira Y, Ikeda N.

Ther Apher Dial. 2014 Jun;18 Suppl 2:8-12. doi: 10.1111/1744-9987.12228.

PMID:
24975889
20.

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.

Nolan CR, Qunibi WY.

Kidney Int Suppl. 2005 Jun;(95):S13-20. Review.

PMID:
15882308

Supplemental Content

Support Center